Josh Kaufman


My clients turn to me as a trusted advisor in critical financing and corporate transactions.

Josh Kaufman's practice focuses on capital markets transactions, primarily in the life sciences and technology verticals. He represents US and foreign private issuers and underwriters in a wide variety of public offerings and private placements. Josh has advised clients on more than 200 financing transactions with an aggregate value in excess of $100 billion. He also counsels clients with respect to public company and corporate governance matters; general corporate and commercial matters; mergers & acquisitions, de-SPACs and other strategic transactions; and dealings with securityholders, securities exchanges and regulatory bodies.

Download full bio 


  • Redx Pharma to Merge With Jounce Therapeutics 

  • Silence Therapeutics – $56.5 Million Registered Direct Offering 

  • Arbor Realty Trust – $123 Million Offering 

  • IN8bio – $40 Million IPO 

  • Sprinklr – $293 Million IPO 

  • View all


  • Columbia Law School
    JD, 2002

  • Columbia Business School
    MBA, 2002

  • Harvard University
    AB, 1998

Admissions & Credentials

New York